In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells

Journal of Controlled Release

Volumn 133, Issue 1, 2009, Pages 4-10

  Ogawara, Ken ichi ^a   Un, Keita ^a   Tanaka, Ken ichi ^b   Higaki, Kazutaka ^a   Kimura, Toshikiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b SHUJITSU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Doxorubicin; Liposome; P glycoprotein; Vascular endothelial cells

Indexed keywords

BEARINGS (STRUCTURAL); BLOOD VESSEL PROSTHESES; CELL DEATH; CELLS; CYTOLOGY; ETHYLENE GLYCOL; GLYCOLS; GLYCOPROTEINS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; SELF ASSEMBLY; TUMORS;

APOPTOSIS; APOPTOTIC CELLS; CANCER CELLS; CYTOTOXIC EFFECTS; DOXORUBICIN; IMMUNOHISTOCHEMICAL STAINING; IN VITRO; IN-VIVO; INTRAVENOUS ADMINISTRATIONS; LIPOSOMAL DOXORUBICIN; MICE MODELS; P-GLYCOPROTEIN; TUMOR CELLS; TUMOR TISSUES; VASCULAR ENDOTHELIAL CELLS;

ENDOTHELIAL CELLS;

DOXORUBICIN; LIPOSOME; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; P-GLYCOPROTEIN; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; VERAPAMIL;

EID: 57049132040     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.09.008     Document Type: Article

References (48)

1. Chung H.C., Rha S.Y., Kim J.H., Roh J.K., Min J.S., Lee K.S., Kim B.S., and Lee K.B. P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res. Treat. 42 (1997) 65-72
2. Lutzky J., Astor M.B., Taub R.N., Baker M.A., Bhalla K., Gervasoni J.E., Rosado M., Stewart V., Krishna S., and Hindenburg A.A. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res. 49 (1989) 4120-4125
3. Montgomery R.B., Guzman J., O'Rourke D.M., and Stahl W.L. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J. Biol. Chem. 275 (2000) 17358-17363
4. Miyoshi Y., Ando A., Takamura Y., Taguchi T., Tamaki Y., and Noguchi S. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int. J. Cancer 97 (2002) 129-132
5. Tsurutani J., Nitta T., Hirashima T., Komiya T., Uejima H., Tada H., Negoro S., Tohda A., Fukuoka M., and Nakagawa K. Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. Lung Cancer 35 (2002) 299-304
6. Christopher F.H. Multiple molecular mechanisms for multidrug resistance transporters. Nature 446 (2007) 479-757
7. Lee E.S., Na K., and Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 103 (2005) 405-418
8. Wang J.C., Goh B.C., Lu W.L., Zhang Q., Chang A., Liu X.Y., Tan T.M.C., and Lee H.S. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol. Pharm. Bull. 28 (2005) 822-828
9. Lim M.N., Lau N.S., Chang K.M., Leong C.F., and Zakaria Z. Modulating multidrug resistance gene in leukaemia cells by short interfering RNA. Singap. Med. J. 48 (2007) 932-938
10. Karwatsky J., Lincoln M.C., and Georges E. A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry 42 (2003) 12163-12173
11. Breier A., Drobná Z., and Barancík M. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells. Neoplasma 45 (1998) 248-253
12. Krishna R., St-Louis M., and Mayer L.D. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int. J. Cancer 85 (2000) 131-141
13. Kobayashi T., Ishida T., Okada Y., Ise S., Harashima H., and Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm. 329 (2007) 94-102
14. Goren D., Horowitz A., Tremach D., Tarshish M., Zalipsky S., and Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6 (2000) 1949-1957
15. Colin de Verdière A., Dubernet C., Nemati F., Poupon M.F., Puisieux F., and Couvreur P. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother. Pharmacol. 33 (1994) 504-508
16. Barraud L., Merle P., Soma E., Lefrançois L., Guerret S., Chevallier M., Dubernet C., Couvreur P., Trépo C., and Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 42 (2005) 736-743
17. Unezaki S., Maruyama K., Hosoda J.I., Nagae I., Koyanagi Y., Nakata M., Ishida O., Iwatsuru M., and Tsuchiya S. Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int. J. Pharm. 144 (1996) 11-17
18. Gabizon A.A., Shmeeda H., and Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 16 (2006) 175-183
19. Heyes J., Hall K., Tailor V., Lenz R., and MacLachlan I. Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery. J. Control. Release 112 (2006) 280-290
20. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
21. Iyer A.K., Khaled G., Fang J., and Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11 (2006) 812-818
22. Northfelt D.W., Dezube B.J., Thommes J.A., Miller B.J., Fischl M.A., Friedman-Kien A., Kaplan L.D., Mond C.D., Mamelok R.D., and Henry D.H. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J. Clin. Oncol. 16 (1998) 2445-2451
23. Schmidt P.G., Adler-Moore J.P., Forssen E.A., and Proffit R.T. In: Lasic D.D., and Papahadjopoulos D. (Eds). Medical Applications of Liposomes (1998), Elsevier Science BV, New York 703-731
24. Working P.K., and Dayan A.D. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Human Exp. Toxicol. 15 (1996) 751-785
25. Gabizon A., Shmeeda H., and Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42 (2003) 419-436
26. Ogawara K., Un K., Minato K., Tanaka K., Higaki K., and Kimura T. Determinants for in-vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Int. J. Pharm. 359 (2008) 234-240
27. Eghbali M., Birnir B., and Gage P.W. Conductance of GABAA channels activated by pentobarbitone in hippocampal neurons from newborn rats. J. Physiol. 552 (2003) 13-22
28. Lim J.G., Lee H.Y., Yun J.E., Kim S.P., Park J.W., Kim S.S., Han J., Park M.J., and Song D.K. Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes. Biochem. Pharmacol. 68 (2004) 901-910
29. Yamaoka K., Tanigawa Y., Tanaka H., and Uno Y. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4 (1981) 879-885
30. Haran G., Cohen R., Bar L.K., and Barenholz Y. Transmembrane ammonium sulfate gradient in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1151 (1993) 201-215
31. Sadasivan R., Morgan R., Fabian C., and Stephens R. Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin. Cancer Lett. 57 (1991) 165-171
32. Gabizon A.A., Chemla M., Tzemach D., Horowitz A.T., and Goren D. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J. Drug Target. 3 (1996) 391-398
33. Mayer L.D., Tai L.C., Ko D.S., Masin D., Ginsberg R.S., Cullis P.R., and Bally M.B. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 49 (1989) 5922-5930
34. Qi J., Wang S., Liu G., Peng H., Wang J., Zhu Z., and Yang C. Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 319 (2004) 1124-1131
35. Shimizu K., Asai T., Fuse C., Sadzuka Y., Sonobe T., Ogino K., Taki T., Tanaka T., and Oku N. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin. Int. J. Pharm. 296 (2005) 133-141
36. Jakobisiak M., and Golab J. Potential antitumor effects of statins. Int. J. Oncol. 23 (2003) 1055-1069
37. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
38. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 14 (2000) 249-257
39. Molema G., Meijer D.L., and de Leij L.F. Tumor vasculature targeted therapies: getting the players organized. Biochem. Pharmacol. 55 (1998) 1939-1945
40. Pandya N.M., Dhalla N.S., and Santani D.D. Angiogenesis: a new target for future therapy. Vasc. Pharmacol. 44 (2006) 265-274
41. Schiffelers R.M., Metselaar J.M., Fens M.H., Janssen A.P., Molema G., and Storm G. Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 7 (2005) 118-127
42. Ogawara K., Rots M.G., Kok R.J., Moorlag H.E., Van Loenen A.M., Meijer D.K., Haisma H.J., and Molema G. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum. Gene Ther. 15 (2004) 433-443
43. Kuldo J.M., Westra J., Asgeirsdóttir S.A., Kok R.J., Oosterhuis K., Rots M.G., Schouten J.P., Limburg P.C., and Molema G. Differential effects of NF-κB and p38 MAPK inhibitors and combinations thereof on TNF-α- and IL-1β-induced proinflammatory status of endothelial cells in vitro. Am. J. Physiol. Cell Physiol. 289 (2005) C1229-1239
44. Oku N., and Namba Y. Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents. Methods Enzymol. 391 (2005) 145-162
45. Sadzuka Y., Sugiyama I., Tsuruda T., and Sonobe T. Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin. Int. J. Pharm. 312 (2006) 83-89
46. Shehata T., Ogawara K., Higaki K., and Kimura T. Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. Int. J. Pharm. 359 (2008) 272-279
47. Yokoe J., Sakuragi S., Yamamoto K., Teragaki T., Ogawara K., Higaki K., Katayama N., Kai T., Sato M., and Kimura T. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int. J. Pharm. 353 (2008) 28-34
48. Hatakeyama H., Akita H., Kogure K., Oishi M., Nagasaki Y., Kihira Y., Ueno M., Kobayashi H., Kikuchi H., and Harashima H. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 14 (2007) 68-77